Company intelligence / Profile preview

Synthorx

La Jolla, California, United Statessanofi.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Synthorx developed a proprietary Expanded Genetic Alphabet platform that enabled the creation of optimized protein therapeutics ("Synthorins") with improved pharmacological properties. Its lead candidate, THOR‑707, an engineered IL‑2 variant for cancer immunotherapy, advanced into clinical trials. The company was acquired by Sanofi in January 2020 before any product reached commercialization

Therapeutic areas: ImmunologyOncology
Modalities: Protein therapeutics (engineered proteins called "Synthorins")Cytokines (notably interleukins such as IL-2 and IL-15 variants)
Industry: Biotech

Beyond the preview

Go deeper on Synthorx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthorx.

Explore the full profile